Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8396253 | 0.80 | HTT (0.54) | ALDH1A1POLBEPHX1 | |
| SCHEMBL8396959 | 0.80 | HTT (0.54) | ALDH1A1POLBEPHX1 | |
| SCHEMBL7389458 | 0.79 | ALDH1A1 (0.52) | ALDH1A1TP53LMNA | |
| SCHEMBL8394927 | 0.79 | HTT (0.56) | ALDH1A1POLBSMN1; SMN2EPHX1 | |
| SCHEMBL3955107 | 0.79 | HSD11B1 (0.62) | ALDH1A1TP53HSD11B1LMNATSHR | |
| SCHEMBL23169576 | 0.76 | TP53 (0.51) | ALDH1A1TAAR1TP53GLATSHR | |
| SCHEMBL8392556 | 0.75 | HTT (0.56) | POLBSMN1; SMN2 | |
| SCHEMBL3951057 | 0.75 | ALDH1A1 (0.49) | ALDH1A1TSHR | |
| SCHEMBL18102739 | 0.73 | ALDH1A1 (0.56) | ALDH1A1POLBLMNASMN1; SMN2EPHX1 | |
| SCHEMBL15444327 | 0.73 | ALDH1A1 (0.56) | ALDH1A1POLBLMNASMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010041700-A1 | Novel succinate derivative compounds useful as cysteine protease inhibitors | BEKKALI YOUNES (US) | 2001-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041700-A1 | Novel succinate derivative compounds useful as cysteine protease inhibitors | SDHA, LONP1, SUCNR1 | ALDH1A1 586/4885TAAR1 4496/4885POLB 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.